Legal status in the United States

Is Semaglutide (oral) legal?

Read at FDA, DEA and WADAPublished by PepVault

Semaglutide (oral) is FDA-approved (Rybelsus, Wegovy and Ozempic, first in 2019), is not a federally controlled substance, and is not named on WADA’s Prohibited List, as of November 18, 2026.

Semaglutide (oral) at a glance

CheckStatus, read Nov 18, 2026
FDA approvalApproved (Rybelsus, 2019)
CompoundingApproved drug; not in shortage
DEA scheduleNot controlled
Sport (WADA)Not named on the list

FDA approval

Oral semaglutide is FDA-approved, first as the Rybelsus tablet in 2019; the Wegovy tablet followed in 2025, and Ozempic tablets, a Rybelsus formulation FDA approved under the Ozempic name on January 30, 2026, are listed on Drugs@FDA under Rybelsus’s application.

The source: “change the name of the product from Rybelsus (formulation R2) to Ozempic (semaglutide) tablets”

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Compounding

Semaglutide is the active ingredient of FDA-approved drugs. FDA wrote on April 1, 2026 that tirzepatide and semaglutide appear neither on the 503B bulks list nor on its drug shortage list, and outsourcing facilities may compound from bulk only what is on that list or in shortage; on April 30, 2026 FDA proposed to keep semaglutide off the 503B bulks list, finding “no clinical need.” FDA’s conditions for pharmacies under 503A include not compounding, “regularly or in inordinate amounts”, what it calls “essentially copies” of a commercially available drug. Being a component of an FDA-approved drug product is one of the three conditions FDA’s page on bulk drug substances gives for 503A.

The source: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”

DEA schedule

It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

Sport (WADA)

The 2026 Prohibited List doesn’t name semaglutide or GLP-1 drugs, and S0, the class for unapproved substances, doesn’t reach an approved drug.

What this means and doesn’t

This page reports what the agencies’ own pages said about Semaglutide (oral) in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.

It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.

Questions

  • Is Semaglutide (oral) FDA approved?

    Oral semaglutide is FDA-approved, first as the Rybelsus tablet in 2019; the Wegovy tablet followed in 2025, and Ozempic tablets, a Rybelsus formulation FDA approved under the Ozempic name on January 30, 2026, are listed on Drugs@FDA under Rybelsus’s application.

  • Is Semaglutide (oral) a controlled substance?

    It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

  • Is Semaglutide (oral) banned in sport?

    The 2026 Prohibited List doesn’t name semaglutide or GLP-1 drugs, and S0, the class for unapproved substances, doesn’t reach an approved drug.

  • What does FDA say about compounding Semaglutide (oral)?

    Semaglutide is the active ingredient of FDA-approved drugs. FDA wrote on April 1, 2026 that tirzepatide and semaglutide appear neither on the 503B bulks list nor on its drug shortage list, and outsourcing facilities may compound from bulk only what is on that list or in shortage; on April 30, 2026 FDA proposed to keep semaglutide off the 503B bulks list, finding “no clinical need.” FDA’s conditions for pharmacies under 503A include not compounding, “regularly or in inordinate amounts”, what it calls “essentially copies” of a commercially available drug. Being a component of an FDA-approved drug product is one of the three conditions FDA’s page on bulk drug substances gives for 503A.

Read next

Track it in the app

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo